ライフサイエンスコーパス: polyinosinic-polycytidylic acid

1 stimulation with TLR ligands (Pam3CSK4, LPS, polyinosinic-polycytidylic acid).

2 ize the synthetic MDA5 agonist/(ds)RNA mimic polyinosinic-polycytidylic acid.

3 al genes induced by a synthetic viral mimic, polyinosinic-polycytidylic acid.

4 icity induced by TNF, lipopolysaccharide and polyinosinic-polycytidylic acid.

5 n of apoptosis by both transfected PRNAs and polyinosinic-polycytidylic acid.

6 administration of low doses of a TLR ligand, polyinosinic-polycytidylic acid.

7 i such as lipopolysaccharide, IFN-gamma, and polyinosinic-polycytidylic acid.

8 on with OVA together with anti-CD40 mAbs and polyinosinic-polycytidylic acid.

9 to CD8(+) T cells following activation with polyinosinic-polycytidylic acid.

10 n hematopoietic cells upon inducing Cre with polyinosinic-polycytidylic acid.

11 FN-alphabeta-inducing viral infections or by polyinosinic:polycytidylic acid.

12 rat virus following brief pretreatment with polyinosinic:polycytidylic acid.

13 DCs after activation with the TLR3 agonist, polyinosinic:polycytidylic acid.

14 intraperitoneally at gestational day 9 with polyinosinic:polycytidylic acid.

15 EW.1W and Wistar Furth) strains induced with polyinosinic:polycytidylic acid.

16 6 production in response to the viral mimic, polyinosinic:polycytidylic acid.

17 o injections with LPS (a bacterial mimic) or polyinosinic-polycytidylic acid (a viral mimic), M-TRAF3

18 eport in this study that TLR3 stimulation by polyinosinic-polycytidylic acid, a double-stranded RNA a

19 murine DCs in response to the dsRNA agonist polyinosinic-polycytidylic acid, a subset of which were

20 In this study, we describe a model of polyinosinic: polycytidylic acid-accelerated lupus nephr

21 Polyinosinic-polycytidylic acid activated IFN regulatory

22 tranded PRNAs 50 nucleotides long as well as polyinosinic-polycytidylic acid activated the RNA-depend

23 dies markedly diminished the cytotoxicity of polyinosinic-polycytidylic acid-activated natural killer

24 llular immunity as well as an enhancement of polyinosinic-polycytidylic acid activation of TLR3.

25 ls have a deficiency in activation following polyinosinic:polycytidylic acid administration in vivo.

26 he synthetic analogue of viral nucleic acid, polyinosinic-polycytidylic acid, also induced IL-6-depen

27 response to inflammatory stimuli, including polyinosinic polycytidylic acid and LPS.

28 ng APC pretreated ex vivo with TLR agonists, polyinosinic-polycytidylic acid and CpG, to prime naive

29 We found that TLR3-ligand polyinosinic-polycytidylic acid and human rhinovirus inf

30 The synthetic dsRNA analog polyinosinic-polycytidylic acid and infection with live

31 ase to athymic WAG-rnu/rnu rats treated with polyinosinic: polycytidylic acid and a monoclonal antibo

32 ls readily develop IDDM after treatment with polyinosinic:polycytidylic acid and a cytotoxic anti-RT6

33 of autoimmune diabetes after treatment with polyinosinic:polycytidylic acid and an antibody that dep

34 DDM can readily be induced by treatment with polyinosinic:polycytidylic acid and depletion of RT6+ T-

35 (lsl-)(DTA) bone marrow with the viral mimic polyinosinic:polycytidylic acid and found a significant

36 sponse to the immunostimulatory nucleic acid polyinosinic:polycytidylic acid and UV light irradiation

37 D8(+) T cell epitope M282-90, a TLR agonist (polyinosinic-polycytidylic acid), and a costimulatory an

38 s, including Sendai virus, the dsRNA mimetic polyinosinic-polycytidylic acid, and LPS all activated d

39 In vivo administration of CpG, polyinosinic-polycytidylic acid, and Pam(3)CSK(4) in com

40 an ISCOMATRIX vaccine with the TLR3 agonist, polyinosinic-polycytidylic acid, and TLR9 agonist, CpG,

41 analog of viral double-stranded RNA (dsRNA) polyinosinic-polycytidylic acid, and type-II interferon-

42 uced in numbers upon in vivo activation with polyinosinic:polycytidylic acid, and have poor survival

43 ld be modulated by crude LPS, peptidoglycan, polyinosinic:polycytidylic acid, and rIFN-gamma in cell

44 major producers of IFN-lambda in response to polyinosinic-polycytidylic acid but are similar to CD1c(

45 XCR1(+) DC were strongly activated by polyinosinic-polycytidylic acid but not LPS, and convers

46 jection of the synthetic double-stranded RNA polyinosinic-polycytidylic acid causes a PPI deficit in

47 Prenatal exposure to polyinosinic:polycytidylic acid causes an imbalanced exp

48 Downregulation upon polyinosinic-polycytidylic acid challenge and expression

49 l effect of IFN-alpha/beta induced by either polyinosinic-polycytidylic acid complex or by lymphocyti

50 ated pathogen-exposed mice intranasally with polyinosinic-polycytidylic acid condensed with poly-l-ly

51 We demonstrated that polyinosinic:polycytidylic acid consistently up-regulate

52 ull cells treated with lipopolysaccharide or polyinosinic-polycytidylic acid coordinate with constitu

53 rejection, and the interferon-inducing agent polyinosinic:polycytidylic acid did not induce allograft

54 bromide/monomycoloyl glycerol liposomes with polyinosinic:polycytidylic acid electrostatically adsorb

55 ecipient exposure to the viral-like adjuvant polyinosinic:polycytidylic acid enhanced anti-FVIII anti

56 beta)-, prion peptide-, double-stranded RNA (polyinosinic-polycytidylic acid)-, HIV-1 Tat-, 1-methyl-

57 ion is observed in macrophages after LPS and polyinosinic:polycytidylic acid in vitro.

58 -activating lipopeptide-2, or a TLR3 ligand, polyinosinic-polycytidylic acid, increased Cox-2 mRNA an

59 macrophage activation by TLR ligands LPS and polyinosinic-polycytidylic acid induced a time-dependent

60 fibrosis, natural killer cell activation by polyinosinic-polycytidylic acid induced cell death to ac

61 Notably, polyinosinic:polycytidylic acid induced nuclear localiza

62 In contrast, a synthetic dsRNA, polyinosinic polycytidylic-acid, induced CD11c(+) DC, bu

63 in LP hosts were markedly less responsive to polyinosinic-polycytidylic acid-induced acute proliferat

64 Polyinosinic-polycytidylic acid-induced antiviral genes

65 ttern recognition receptors was required for polyinosinic-polycytidylic acid-induced IFN-alpha/beta p

66 Compound II inhibited polyinosinic-polycytidylic acid-induced immune activatio

67 Importantly, we discovered that the polyinosinic-polycytidylic acid-induced increase in prod

68 essing RIPK1 D138N are resistant to TNF- and polyinosinic-polycytidylic acid-induced necroptosis in v

69 A defect in polyinosinic-polycytidylic acid-induced TLR3 responses c

70 induced or synthetic dsRNA-based viral mimic polyinosinic:polycytidylic acid-induced expression of pr

71 , unlike those transfused in the presence of polyinosinic:polycytidylic acid-induced inflammation.

72 w-derived macrophages; however, priming with polyinosinic-polycytidylic acid induces it and confers n

73 Instead, challenge of TM with LPS or polyinosinic-polycytidylic acid induces MAPK, AP-1, and

74 of stimulating anti-CD40 Ab and TLR3 ligand polyinosinic-polycytidylic acid induces protective respo

75 Here we show that TLR3 activation by polyinosinic:polycytidylic acid induces up-regulation of

76 ytomegalovirus infection or after repetitive polyinosinic-polycytidylic acid injection.

77 eritoneal injection of lipopolysaccharide or polyinosinic:polycytidylic acid into mice, mimicking bac

78 lity of RIG-I to respond to stimulation with polyinosinic:polycytidylic acid is abolished when its in

79 TLR3 activation with polyinosinic-polycytidylic acid led to comparable or eve

80 Treatment with CVB3 and polyinosinic:polycytidylic acid led to higher IFNbeta ex

81 g HEK293 cells to stimulation with Pam3CSK4, polyinosinic-polycytidylic acid, LPS, and ODN2006, respe

82 s gene greatly sensitizes cells to cytosolic polyinosinic/polycytidylic acid-mediated induction of ty

83 31 breast cancer cells, we demonstrated that polyinosinic:polycytidylic acid-mediated activation of T

84 r LPS to shorten allograft survival, whereas polyinosinic:polycytidylic acid mediates its effects thr

85 The observed protective effect of polyinosinic-polycytidylic acid on liver fibrosis was di

86 Treatment with polyinosinic-polycytidylic acid or a combination of mono

87 Moreover, treatment with polyinosinic-polycytidylic acid or interferon gamma enha

88 ted a cell-associated Ag upon stimulation by polyinosinic-polycytidylic acid or R848, likewise to wha

89 nal antibody and then exposed them to either polyinosinic:polycytidylic acid or a diabetogenic virus

90 accelerated following the administration of polyinosinic:polycytidylic acid or allogeneic cells (gra

91 DC) maturation induced by LPS, as opposed to polyinosinic:polycytidylic acid or cytosine-phosphate-gu

92 or ATI-free diet and in mice given low-level polyinosinic:polycytidylic acid or dextran sodium sulfat

93 inistered systemically with the TLR3 agonist polyinosinic:polycytidylic acid or were given subcutaneo

94 domain-containing adapter inducing IFN-beta (polyinosinic-polycytidylic acid) or MyD88 (imiquimod), d

95 27(p28) after engagement of either the TLR3 (polyinosinic-polycytidylic acid) or TLR4 (LPS) receptor.

96 during virus infection, cellular exposure to polyinosinic-polycytidylic acid, or TBK1 overexpression.

97 ed with macrophage-activating lipopeptide-2, polyinosinic-polycytidylic acid, or UVB (15 mJ/cm(2)), b

98 In the absence of polyinosinic:polycytidylic acid, or in the presence of a

99 We show that IFN-alpha and polyinosinic:polycytidylic acid (p-I:C) synergize with t

100 in conjunction with the Th1-biased adjuvant polyinosinic:polycytidylic acid (pI:C).

101 MIA was induced in C57BL/6 mice by polyinosinic-polycytidylic acid (PIC) injected during em

102 oaded with Torula Yeast RNA (TYRNA)(640 nm), polyinosinic: polycytidylic acid (pIC)(680 nm), or splic

103 To test whether retinoic acid (RA) and polyinosinic:polycytidylic acid (PIC), an inducer of int

104 Among the compounds tested, polyinosinic:polycytidylic acid (PIC, a Toll-like recept

105 blast-like synoviocytes were stimulated with polyinosinic-polycytidylic acid (poly [I-C]) after trans

106 Polyinosinic-polycytidylic acid (Poly I:C) or IFN-gamma

107 Polyinosinic-polycytidylic acid (poly I:C) or IFN-gamma

108 y in murine astrocyte primary cultures using polyinosinic-polycytidylic acid (poly I:C), a synthetic

109 Polyinosinic-polycytidylic acid (poly I:C), a TLR3 ligan

110 t and human islets with dsRNA in the form of polyinosinic-polycytidylic acid (poly IC) and IFN-gamma

111 y, we assessed the effect of the TLR3 ligand polyinosinic-polycytidylic acid (poly IC) on CD8 T cell

112 The synthetic dsRNA molecule polyinosinic-polycytidylic acid (poly IC) stimulates bet

113 randed RNA (dsRNA) (in the form of synthetic polyinosinic-polycytidylic acid (poly IC)) on islet expr

114 ly induced by the Toll-like receptor ligands polyinosinic-polycytidylic acid (poly(I:C)) and flagelli

115 an absence of response to TLR3 activation by polyinosinic-polycytidylic acid (poly(I:C)) and related

116 tured microglia responded to synthetic dsRNA polyinosinic-polycytidylic acid (poly(I:C)) by increasin

117 ecific abrogation of macrophage responses to polyinosinic-polycytidylic acid (poly(I:C)) resulting fr

118 of systemic IFN-beta expression elicited by polyinosinic-polycytidylic acid (poly(I:C)) treatment or

119 lung fibroblasts, the synthetic TLR3 ligand polyinosinic-polycytidylic acid (poly(I:C)), a dsRNA ana

120 TLR3 is activated by viral dsRNA and polyinosinic-polycytidylic acid (poly(I:C)), a synthetic

121 Polyinosinic-polycytidylic acid (poly(I:C)), an analog o

122 -regulates the induction by a viral mimetic, polyinosinic-polycytidylic acid (poly(I:C)), of the endo

123 ry molecules such as LPS, lipoteichoic acid, polyinosinic-polycytidylic acid (poly(I:C)), TNF-alpha,

124 P2), expressed in the presence or absence of polyinosinic-polycytidylic acid (poly(I:C)), which elici

125 Anti-CD40 also increased polyinosinic-polycytidylic acid (poly(I:C))-inducible IF

126 64.7 macrophage cells stimulated with LPS or polyinosinic-polycytidylic acid (poly(I:C)).

127 opolysaccharide (LPS, bacterial antigen) and polyinosinic-polycytidylic acid (poly(I:C), viral antige

128 Escherichia coli (TLR4), lipoprotein (TLR2), polyinosinic-polycytidylic acid (poly-IC) (TLR9), and th

129 ctive cytokine responses upon challenge with polyinosinic-polycytidylic acid (poly-IC).

130 As polyinosinic-polycytidylic acid (poly[I:C]), which mimic

131 Of the TLRs ligands tested, the TLR3 ligand, polyinosinic/polycytidylic acid (Poly(I:C)), most highly

132 Polyinosinic:polycytidylic acid (poly I:C), a synthetic

133 ts and develop diabetes after treatment with polyinosinic:polycytidylic acid (poly I:C), a synthetic

134 that lipopolysaccharide, a TLR4 ligand; and polyinosinic:polycytidylic acid (poly I:C), a TLR3 ligan

135 r ability to prime T cells: the TLR3 ligand, polyinosinic:polycytidylic acid (poly I:C), and immunost

136 aradigm, we treated timed-pregnant mice with polyinosinic:polycytidylic acid (Poly I:C), which simula

137 llenged with virus or with the viral mimetic polyinosinic:polycytidylic acid (poly I:C).

138 inflammatory cytokine induction elicited by polyinosinic:polycytidylic acid (poly I:C; a synthetic d

139 toll-like receptor (TLR) agonists, we found polyinosinic:polycytidylic acid (poly IC) to be the most

140 dsRNA [polyinosinic:polycytidylic acid (poly IC)]-stimulated in

141 c acid) (PLGA) nanoparticles adjuvanted with polyinosinic:polycytidylic acid (poly(I:C) as an adjuvan

142 Double-stranded RNA and the synthetic analog polyinosinic:polycytidylic acid (poly(I:C)) bind and act

143 esponse to stimulation by the dsRNA analogue polyinosinic:polycytidylic acid (poly(I:C)) was dependen

144 necrosis factor (TNF), lipopolysaccharide or polyinosinic:polycytidylic acid (poly(I:C))-induced necr

145 on of NK cells by influenza-infected DCs and polyinosinic:polycytidylic acid (poly(I:C))-treated DCs

146 y reported that viral-like inflammation with polyinosinic polycytidylic acid [poly (I:C)] significant

147 Polyinosinic-polycytidylic acid [Poly (I:C)], a dsRNA re

148 edge, we demonstrate for the first time that polyinosinic-polycytidylic acid [poly (I:C)], a syntheti

149 Alpha/beta interferon induction by polyinosinic-polycytidylic acid [poly(I-C)] treatment ef

150 mice treated with the IFN-alpha/beta inducer polyinosinic-polycytidylic acid [poly(I-C)].

151 or peptidoglycan (PGN; a TLR 2 agonist) and polyinosinic-polycytidylic acid [poly(I:C); a TLR3 agoni

152 diator production induced by the viral mimic polyinosinic-polycytidylic acid [poly(I:C)] in primary h

153 Polyinosinic-polycytidylic acid [poly(I:C)] is a known i

154 of the study was to evaluate the activity of polyinosinic-polycytidylic acid [poly(I:C)] on IL-17A pr

155 Application of polyinosinic-polycytidylic acid [poly(I:C)] or LPS induc

156 antigen (GAA) epitopes and administration of polyinosinic-polycytidylic acid [poly(I:C)] stabilized b

157 n regulatory factor 3 in response to LPS and polyinosinic-polycytidylic acid [poly(I:C)] stimulus, co

158 lovirus (MCMV) infection and the TLR3 ligand polyinosinic-polycytidylic acid [poly(I:C)] were used to

159 hat preconditioning with the synthetic dsRNA polyinosinic-polycytidylic acid [poly(I:C)], a mimetic o

160 CD8+ cells and was mimicked by injection of polyinosinic-polycytidylic acid [poly(I:C)], an inducer

161 port that a potent inducer of IFN-alphabeta, polyinosinic-polycytidylic acid [poly(I:C)], led to the

162 se combinations were resiquimod (R-848) plus polyinosinic-polycytidylic acid [Poly(I:C)], R-848 plus

163 by treatment of cells or fish with the dsRNA polyinosinic-polycytidylic acid [poly(I:C)], which induc

164 phorothioate oligonucleotide [Poly(dT)], and polyinosinic-polycytidylic acid [Poly(I:C)].

165 ied in Montanide ISA51 with or without TLR3 (polyinosinic-polycytidylic acid [poly-IC]), TLR4 (monoph

166 in humans to synthetic double-stranded RNA (polyinosinic:polycytidylic acid [poly IC] stabilized wit

167 ured vascular smooth muscle cells (VSMCs) to polyinosinic:polycytidylic acid [poly(I:C)] and was nece

168 uvant to boost CD8 T-cell function; however, polyinosinic:polycytidylic acid [poly(I:C)] can also sup

169 served in mice born to mothers injected with polyinosinic:polycytidylic acid [poly(I:C)] during pregn

170 ing the Toll-like receptor 3 (TLR-3) agonist polyinosinic:polycytidylic acid [poly(I:C)] in the SN of

171 Tlr4(-/-) mice primed with TLR3 agonist polyinosinic:polycytidylic acid [poly(I:C)] to induce pr

172 n of TLR4 and TLR3 signaling through LPS and polyinosinic:polycytidylic acid [poly(I:C)] treatments r

173 n vivo administration of the synthetic dsRNA polyinosinic:polycytidylic acid [poly(I:C)], but not lip

174 In combination, synthetic dsRNA (polyinosinic-polycytidylic acid, poly(I-C)) and interfer

175 he effects of double-stranded RNA (synthetic polyinosinic-polycytidylic acid; poly(I-C)) on macrophag

176 Activation of TLR3 by polyinosinic-polycytidylic acid (polyI:C) leads to induc

177 by the synthetic double-stranded RNA ligand, polyinosinic-polycytidylic acid (polyI:C), leads to decr

178 une programming of fetal loss in response to polyinosinic:polycytidylic acid (polyI:C), a viral mimic

179 mmune activation (MIA) during pregnancy with polyinosinic:polycytidylic acid (polyI:C).

180 nt study, we employed the viral RNA mimetic (polyinosinic-polycytidylic acid [polyI:C]) to emulate vi

181 Polyinosinic-polycytidylic acid (PolyIC), a "mimic" of d

182 virus infection and treatment of cells with polyinosinic-polycytidylic acid (polyIC; a dsRNA mimetic

183 uction, whereas CpG oligodeoxynucleotide and polyinosinic:polycytidylic acid primarily stimulated Th1

184 nd did not decrease in spleen in response to polyinosinic-polycytidylic acid-promoted hepatitis.

185 XCL4-moDCs exclusively upon stimulation with polyinosinic-polycytidylic acid, R848, and CL075 ligands

186 Challenge with polyinosinic-polycytidylic acid results in a rapid and s

187 g via TLR7) and MyD88-independent receptors (polyinosinic:polycytidylic acid signaling via TLR3 or ds

188 duce immune responses via active delivery of polyinosinic-polycytidylic acid sodium salt (poly I:C) t

189 M-CSF, rmIFN-gamma, rmIFN-alpha, rmIL-4, and polyinosinic-polycytidylic acid stabilized by lysine and

190 1 and given every 3 weeks with intramuscular polyinosinic-polycytidylic acid stabilized by lysine and

191 e viral mimic synthetic double-stranded RNA (polyinosinic:polycytidylic acid stabilized with poly-l-l

192 viral mimic, synthetic double-stranded RNA (polyinosinic:polycytidylic acid stabilized with poly-L-l

193 These data indicate that CpG DNA and polyinosinic-polycytidylic acid stimulate different type

194 In rainbow trout RTG-2 and RTS-11 cells, polyinosinic-polycytidylic acid stimulation resulted in

195 In contrast, polyinosinic:polycytidylic acid strongly represses CpG's

196 omodulators (monomycolyl glycerol analog and polyinosinic-polycytidylic acid) that efficiently induce

197 the effects of the inhaled viral TLR ligands polyinosinic-polycytidylic acid (TLR3) and resiquimod (T

198 including LPS (TLR4), peptidoglycan (TLR2), polyinosinic-polycytidylic acid (TLR3), CpG DNA (TLR9),

199 nistration of the TLR agonists LPS (TLR4) or polyinosinic:polycytidylic acid (TLR3) to mice treated w

200 LR7/8 activation, but selectively spared the polyinosinic-polycytidylic acid/TLR3 pathway.

201 s were coinjected with TLR2 (Pam3Cys), TLR3 (polyinosinic:polycytidylic acid), TLR4 (LPS), or TLR9 (C

202 t to necroptosis after stimulation with LPS, polyinosinic-polycytidylic acid, TNF-alpha, or IFN-beta

203 nation, even in the presence of anti-CD40 or polyinosinic:polycytidylic acid to induce DC maturation.

204 l growth factors and innate immune activator polyinosinic:polycytidylic acid to induce endothelial ce

205 However, KCs isolated from polyinosinic:polycytidylic acid-treated mice expressed s

206 Polyinosinic-polycytidylic acid treatment also ameliorat

207 Polyinosinic-polycytidylic acid treatment of RAG(-/-) mi

208 cted in primary head kidney leukocytes after polyinosinic-polycytidylic acid treatment, whereas a mod

209 lysaccharide, cytosine-phosphate-guanine, or polyinosinic:polycytidylic acid) using flow cytometry an

210 The Toll-like receptor 3 ligand, polyinosinic-polycytidylic acid, was used to activate in

211 RNA viruses (polyuridine) and dsRNA viruses (polyinosinic-polycytidylic acid) were significantly weak

212 r subsequent transfusions in the presence of polyinosinic:polycytidylic acid, whereas anti-hGPA level

213 head kidney leukocytes when stimulated with polyinosinic:polycytidylic acid, whereas group II IFN wa

214 Treatment of infected mice with a complex of polyinosinic-polycytidylic acid with poly-L-lysine and c